中文

海辰药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-25
ItemAmountY/Y
Revenue¥0.16B+12.4%
Gross profit¥0.13B
Operating income¥0.02B
Net income¥0.02B+9.2%
Gross margin78.4%Net margin 10.2%
Revenue Q/Q-19.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.03B21.6%
R&D¥0.00B2.8%
SG&A¥0.10B61.2%
Tax & other¥-0.00B-0.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

奥联电子美联新材天铁科技熙菱信息江龙船艇移为通信万里马华凯易佰新雷能ST朗进欧普康视利安隆

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies